Outcome of Board Meeting

L I N C O L N P H A R M A C E U T IC A L S L T D . H E A L T H C A R E F O R A L L D a t e : O c t o b e r 2 9 , 2 0 2 6 T o , T o , T h e o f S e r v ic e , D e p a r t m e n t C o r p o r a t e T h e M a n a g e r , L is t in g D e p a r t m e n t , N a t io n a l S t o c k o f I n d i a L im i t e d B S E L im i t e d , E x c h a n g e ( N S E ) , 1 s t N e w R o t u n d a P h ir o z e F lo o r , T r a d in g R in g , B u ild in g , l , P la z a , C - B lo c k - G , B a n d r a - K u r la T o w e r , D a la l S t r e e t , M u m b a i - 4 0 0 0 0 1 . E x c h a n g e J e e je e b h o y C o m o le x . B a n d r a I E \ . M u m b a i- 4 0 0 0 5 1 . S v m b o l - U N C O L N S e r io C o d e - 5 3 1 6 3 3 D e a r S ir , S U B .: O U T C O M E O F B O A R D M E E T I N G . F u r t h e r t o o u r in t im a t io n d a t e d O c t o b e r t o 3 3 o f t h e S e c u r it ie s a n d 2 2 , 2 0 2 6 , E x c h a n g e p u r s u a n t R e g u la t io n B o a r d o f I n d ia a n d D is c lo s u r e 2 0 1 5 C 'S E B I L is t in g ( L is tin g O b lig a t io n s R e q u ir e m e n t s ) R e g u la t io n s , w e w o u ld lik e t o in f o r m t h a t t h e B o a r d o f D ir e c t o r s o f t h e a t it s h e ld t o d a y C o m p a n y m e e t in g R e g u la t io n s '\ t.e , o n O c t o b e r h a v e c o n s id e r e d a n d t h e u n - a u d it e d fin a n c ia l r e s u lt s T h u r s d a y , 2 9 , 2 0 2 6 , a p p r o v e d a n d o f t h e f o r t h e a n d h a lf e n d e d o n 3 0 , 2 0 2 6 S e p t e m b e r (s t a n d a lo n e c o n s o lid a t e d ) C o m p a n y q u a r t e r y e a r w it h t h e lim it e d r e v ie w f r o m a u d it o r s t h e r e o n . a lo n g r e p o r t In t e r m s o f 4 7 o f t h e t h e w ill p u b lis h a n e x t r a c t o f u n - a u d it e d R e g u la t io n L is t in g R e g u la t io n s , C o m p a n y s t a n d a lo n e a n d c o n s o lid a t e d fin a n c ia l r e s u lt s f o r t h e a n d h a lf e n d e d o n 3 0 , 2 0 2 6 . q u a r t e r y e a r S e p t e m b e r T h e u n - a u d it e d fin a n c ia l r e s u lt s a n d w ill b e a v a ila b le a t C o m p a n y 's w e b s it e ( s t a n d a lo n e c o n s o lid a t e d ) w w w .lin c o lo o b a r m a .c o m . T h e u n - a u d it e d fin a n c ia l r e s u lt s a n d w ill b e a v a ila b le a t C o m p a n y 's w e b s it e a t (s t a n d a lo n e c o n s o lid a t e d ) w e e n c lo s e h e r e w it h fin a n c ia l f o r t h e a f o r e s a id F u r t h e r , q u a r t e r . w w w .lin c o ln p h a r m a .c o m . h ig h lig h t s T h e o f t h e B o a r d o f D ir e c t o r s o f t h e c o m m e n c e d a t i l a n d c o n c lu d e d a t 1 2 : 1 .S p , M , M e e t in g C o m p a n y 0 0: A ,M t a k e t h e s a m e o n r e c o r d s . K in d ly y o u r T h a n k in g y o u , Y o u r s f a it h f u lly , O f f i c e r C o m p a n y S e c r e t a r y C o m p li a n c e & E n c l: A / a O f fic e : "L in c o ln H o u s e " , 8 /h . S c ie n c e R o a d , S o ta , A h m e d a b a d - 3 8 0 0 6 0 , In d ia . e g d . S a ly a m C o m p le x , C ity G u 1a ra t, h o n e : + 9 1 - 7 9 - 4 1 0 7 8 0 0 0 I C IN L 2 4 2 3 0 G J 19 9 5 P L C 0 2 4 2 8 8 - m a il : I W e b s it e : in fo @ lin c o ln p h a r m a .c o m w w w .lin c o ln p h a r m a .c o m N o . 4 1 0 / 1, 8 /h . S h a n k u 's W a te r P a r k , a c to r y : S u r v e y B a liy a s a n . e h s a n a - A h m e d a b a d D is t. M e h s a n a - 3 8 2 7 3 2 . S ta te , In d ia . G u ja r a t H ig h w a y , h o n e : + 9 1- 7 0 9 6 5 2 3 6 5 7 I E - m a il: a d m in lp lu n it3 1 g lm c o ln p h a r m a .c o m LINCOLN PHARMACEUTICALS LIMITED Regd. Office: ftUNCOL.N HOUSE" Behind Satyam Complex, Scieoce Qty Road, Sola, Ahmedabad-380060. CIN: l24230GJ1995PLC024268, Ph. No.: +91·79-4107-8000, Website: www.lincolnnharma.com E·Mall: I lincolnnro>nna.com Statement of Standalone Un·Audrt:ed Financial Results for the ouarter and Half Year Ended on 30-Se mber-2026, '" In Lakhs uarter l:nded Half Y"r Ended Year fnded Sr. No. Particulars 30/09/2026 30/06/2026 30/09/2025 30/09/2026 30/09/2025 31/03/2026 'Un-Audited' 1un-Audited' 'Un·Audltedl tun-Auditedl tun-Audltedl (Audited} 1 Income A) Revenue fTOm Operations 19,134.51 11,na.21 16,336.39 36,862.n 31.7'43.06 67,102.99 B' other Income 953.40 2 426.46 nJ.21 J 379.86 2 250.38 3 345.40 Total Income 20 087.91 20,154.67 17 059.60 40.242.58 33993.44 70 .39 2 Expenses A) Cost of Matenal C.OOSUmed 7,747.06 5,857.86 5,719.90 13,604.92 11,816.83 23,957.41 B) Purchase of Stock·In·Trade 2,686.47 2,093.36 2,172.27 4,n9.83 3,755.33 7,902.55 C) O'lar,oes In Inventories of Anlshed Goods, Stock (643.82) 563.09 (217.61) (80.73) (959.17) (743.96) In-Trade and WIP DJ Employee Benefits Expenses 3,129.27 3,331.03 3,035.60 6,460.30 6,21..1.. ._2.8, 12,518.86 ,.._., E) Finance Costs 31.79 25.87 23.07 57.66 101.29 F) Deprecation and Amortisation Expense 388.44 388,.43 361.90 n6.87 1,+49.96 G)OthefEx- 3 846.85 3 139.65 3 083.39 6 986.50 5 995.50 13 699.78 Total l!xoenses 17,186.06 15,399.29 14 178.52 32.585.35 27 573.44 58 885.89 Profit I (loss) Before Exceptional Items & Tax 3 2,901.85 4,755.38 2,881.08 7,657.23 6,420.00 11,562.50 4 esce al Items Nd NH Nil NH Nil NH s Profit I (loss) after Exceptional Items but 2,901.85 4,755.38 2,881.08 7,657.23 6,420.00 11,562.50 Befn-Tait (3-4l Tax Expense 6 A) Current Tax 769.90 535.30 861.90 1,305.20 1,274.20 2,737.10 B) Deferred Tax {Net) (&4.79) 596.63 (12.45) 511.&4 346.65 (3.09) C) Short/ (Excess) Provision of Income Tax Of 174.13 NH 33.23 174.13 33.23 39.11 7 Net Profit 1 •Loss For The Period 5-6 2 042.61 3 623.45 1 998.40 5 666.06 4 765.92 8 789.38 Other C,omprehenslve Income {Net Of Tax) Items that will not be reclassified to 41.87 41.88 2.29 83.75 4.58 167.50 8 subseQuenttv to orofit and loss Ite-m·-s tha. t wiN be redasslfled subseQuent!y to "" NI N,I "" Total Comnrehenslve Income , 084.48 3 665.33 , 000.69 5.749.81 4 770.50 8 956.88 Pakl·Up Equity Share capital (Face Value Of Rs. 10/· 10 2,002.97 2,002.97 2,002.97 2,002.97 2,002.97 2,002.97 ""'' 11 Other EQUlty 73,760.23 Earnings Per Share (of Rs. 10/· Each) (Not Annualised) (a) Basic 10.20 18.09 9.98 28.29 23.79 43.88 , .se lb\ Diluted 10.20 18.09 28.29 23.79 '43.88 The above unaudited standalone financial results of the c.ompany for the quarter and half year ended on September 30, 2026 have been reviewed and I recommended by the audit committee and approved by the board of directors of the C,ompany In their meeting held on Thufsday, October 29, 2026. The audd:or have carried out an limited review of the said financial results. This statement has been Pfepared In acco<'dance with the Companies (Indian Accounting Sblndards) Rules, 2015 (Ind AS), presQibed under section 133 of the C,ompanles Ni, 2013, and other recognized accounting practices and polldes to the extent applicable. 3 The c:,,m has a Si le business rnent na 'Pharmaceutlcal Business'. 4 Tl1e figures for the previous period / year have been regrouped J redasslfled, whereYef nec:es.sary to conform to current period J year das.511\cation. �l>-\lMAC<'"�- For Uncoln Phannaceutlails Uml� 3� o AHMEOABAO l> 0 r- ,.. , ..: (� '). Mahendl'ill G. Patel Place: Ahmedabad Managing Dirfflor Date: October 29 2026 OIN: 00104706 Standalone Balance Sheet 1, in Lakhs ,.,.a, "" a, Sr. No. Particulars 30/09/2026 31/03/2026 (Un-Audited) (Audited) A ASSETS 1 Non-Current Assets (A) Property, Plant and Equipment 18,965.82 18,986.38 (B) Right to use Asset 15.66 16.74 (C) Capital Work-In-Progress 666.06 522.84 (D) Other Intangible Assets 105.06 91.95 (E) Financial Assets (i) Investments 5.26 5.26 (ii) Loans 9,034.92 10,694.01 (iii) Others Financial Assets 104.95 132.23 Fl Other Non-Current Assets 3,219.07 290.16 Sub Total Non-Current Assets 32.116.BO 30,739.57 2 Current Assets (A) Inventories 8,166.89 8,010.56 (B) Financial Assets (i) Investments 24,457.65 20,854.08 (ii) Trade Receivables 16,322.51 16,058.22 (iii) Cash and Cash Equivalents 2,120.77 2,109.01 (iv) [Showing first 8,000 characters — download PDF for full document]